Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe

Autor: Alice B. Gottlieb, Ara Dikranian, Astrid van Tubergen, Lara Fallon, Laraine Aikman, Timothy W. Smith, Jordi Gratacós, Linda H. Chen, Birol Emir
Přispěvatelé: Interne Geneeskunde, MUMC+: MA Reumatologie (9), RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
Arthritis
Disease
DISEASE
0302 clinical medicine
Quality of life
QUALITY-OF-LIFE
Immunology and Allergy
030212 general & internal medicine
Practice Patterns
Physicians'
Depression (differential diagnoses)
MULTINATIONAL ASSESSMENT
Middle Aged
PREVALENCE
Europe
Rheumatoid arthritis
Antirheumatic Agents
Female
Public Health
BURDEN
Adult
medicine.medical_specialty
Immunology
Therapeutics
Health status
Medication Adherence
Time-to-Treatment
03 medical and health sciences
Psoriatic arthritis
Rheumatology
Internal medicine
medicine
MANAGEMENT
Humans
Patient Reported Outcome Measures
Disease burden
Aged
030203 arthritis & rheumatology
Biological Products
Health Services Needs and Demand
business.industry
CLINICAL-FEATURES
Arthritis
Psoriatic
medicine.disease
Health Surveys
United States
RHEUMATOID-ARTHRITIS
MYOCARDIAL-INFARCTION
Patient-reported outcome measures
RISK-FACTORS
psoriatic
business
Surveys and questionnaires
Zdroj: Rheumatology International, 39(1), 121-130. Springer
Rheumatology International
ISSN: 0172-8172
DOI: 10.1007/s00296-018-4195-x
Popis: Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatment patterns on patient-reported outcomes in the US and 5 European countries (EU5; France, Germany, Italy, Spain, UK) were evaluated. Respondents from the 2016 National Health and Wellness Survey received advanced therapies (e.g., biologic disease-modifying antirheumatic drugs [DMARDs]), other therapies, (e.g., conventional synthetic DMARDs), or no treatment. Assessments included demographics, disease severity (patient-reported), comorbidities (Charlson Comorbidity Index), health status (Short Form-36 Health Survey), depression (Patient Health Questionnaire-9), work productivity (Work Productivity and Activity Index), and treatment adherence (Morisky Medication Adherence Scale-8). Overall, 1037 respondents from the US and 947 respondents from the EU5 were included. Of these, 21.7% US and 7.3% EU5 respondents received advanced therapies; 16.6% and 28.5%, other therapies; and 61.7% and 64.2%, no treatment, respectively. During treatment with advanced or other therapies, 40.8–54.7% US and 57.7–58.9% EU5 respondents self-reported moderate or severe PsA. Respondents receiving advanced therapies had the highest Charlson Comorbidity Index score (US, 1.25; EU5, 1.42); the lowest scores were with no treatment (0.52 and 0.49, respectively). Employment was lowest with other therapies (US, 47.7%; EU5, 41.1%). Overall work impairment was reported by 57.9% US and 62.6% EU5 respondents receiving advanced therapies. Medication adherence was generally low in the US and medium in the EU5 (Morisky Medication Adherence Scale-8: low, US 40.1–46.7%, EU5, 29.0–35.2%; medium, US 29.3–36.1%, EU5 37.8–49.3%; high, US 23.8–24.0%; EU5, 21.7–27.0%). Advanced and other therapies reduced PsA severity; however, > 40% of respondents reported moderate or severe PsA during treatment. Better management and adherence may reduce unmet need and disease burden. Further work is required to improve PsA diagnosis and time to treatment initiation. Electronic supplementary material The online version of this article (10.1007/s00296-018-4195-x) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: